Lantern Pharma (LTRN) Cash from Financing Activities (2019 - 2025)

Lantern Pharma (LTRN) has 6 years of Cash from Financing Activities data on file, last reported at $526459.0 in Q4 2025.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $526459.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $538453.0 (up 707.15% YoY) and the FY2025 annual result came in at $1.5 million, up 2145.9% from the prior year.
• Cash from Financing Activities rose to $526459.0 in Q4 2025, from $11994.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $64.3 million in Q1 2021 to a low of -$2.2 million in Q1 2022.
• A 4-year average of $8.8 million and a median of $11994.0 in 2024 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 60973.42% in 2021, down 334309.58% in 2021.
• Tracing LTRN's Cash from Financing Activities over 4 years: stood at -$872809.0 in 2021, then slumped by 150.05% to -$2.2 million in 2022, then surged by 100.55% to $11994.0 in 2024, then surged by 4289.35% to $526459.0 in 2025.
• The last three Cash from Financing Activities figures came in at $526459.0 (Q4 2025), $11994.0 (Q3 2024), and $54716.0 (Q1 2024), per Business Quant data.